Bristol-Myers details its failure on Checkmate 451, highlighting a bleak future for their checkpoint combo

We found out last fall that Bristol-Myers Squibb’s combination of its PD-1/CTLA-4 drugs Opdivo and Yervoy failed to work as a maintenance therapy for small cell lung cancer. Today, we got the details. And it wasn’t pretty.